Read Also: Teva Reports Early Skin Repigmentation Data, Sets Stage For Next Trial Forte Biosciences Inc.
(NASDAQ:FBRX) on Thursday reported positive topline results from its Phase 1b trial evaluating FB102 in patients with vitiligo, a chronic autoimmune disorder where the immune system attacks melanocytes (pigment-producing cells).
The investigational therapy demonstrated statistically significant improvements in facial repigmentation, early treatment responses, and a favorable safety profile.
FB102 Met Primary Endpoint With Significant Improvement The Phase 1b study enrolled 43 participants, randomizing 32 to FB102 and 11 to placebo.
The primary endpoint measured the mean percentage improvement from baseline in the Facial Vitiligo Area Scoring Index (FVASI).
